A Difficult Case of Calcineurin Inhibitor Neurotoxicity Post-Haploidentical HCT With a Successful Novel Solution: Cytotoxic T-Lymphocyte-Associated Protein 4-Immunoglobulin Blockade for GVHD Prophylaxis

A Difficult Case of Calcineurin Inhibitor Neurotoxicity Post-Haploidentical HCT With a Successful Novel Solution: Cytotoxic T-Lymphocyte-Associated Protein 4-Immunoglobulin Blockade for GVHD Prophylaxis

Post–allogeneic hematopoietic cell transplant (HCT) immunosuppression regimens are given as graft-versus-host disease (GVHD) prophylaxis. Most GVHD prophylaxis regimens are based on calcineurin inhibitors (CNIs). Unfortunately, CNIs are associated with significant associated morbidity, frequently ca...

Descripció completa

Dades bibliogràfiques
Autors principals:	Kaitlyn Dykes, Dimitrios Tzachanis, Divya Koura
Format:	Article
Idioma:	English
Publicat:	SAGE Publishing 2024-07-01
Col·lecció:	Cell Transplantation
Accés en línia:	https://doi.org/10.1177/09636897241265249

Ítems similars

GVHD PROPHYLAXIS WITH METHOTREXATE IN HAPLOIDENTICAL HCT USING POSTTRANSPLANT CYCLOPHOSPHAMIDE: A PHASE IB/II CLINICAL TRIAL (NCT04622956)
per: G Fatobene, et al.
Publicat: (2024-10-01)

The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis
per: Francesca Lorentino, et al.
Publicat: (2017-04-01)

Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70
per: Philip H. Imus, et al.
Publicat: (2019-09-01)

GVHD Prophylaxis 2020
per: Mahasweta Gooptu, et al.
Publicat: (2021-04-01)

P1396: EFFICACY AND SAFETY COMPARISON OF CALCINEURIN INHIBITORS USED FOR GVHD PROPHYLAXIS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH THALASSEMIA
per: S. Zhumatayev, et al.
Publicat: (2022-06-01)

Cellular Strategies for Separating GvHD from GvL in Haploidentical Transplantation
per: Mauro Di Ianni, et al.
Publicat: (2024-01-01)

PT-Cy combined with ruxolitinib and tocilizumab prevents aGVHD after haploidentical HSCT
per: BAI Haocheng, et al.
Publicat: (2020-09-01)

P1333: PLASMA EXCHANGE, IMMUNOGLOBULIN & PRE-TRANSPLANT IMMUNOSUPPRESSION: AN EFFECTIVE DESENSITISATION STRATEGY FOR DSA ALLOANTIBODIES IN HAPLOIDENTICAL HCT FOR PAEDIATRIC RED CELL DISORDERS
per: D. Dexter, et al.
Publicat: (2022-06-01)

Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients
per: Yu Wang, et al.
Publicat: (2019-09-01)

Cotransplantation of haploidentical hematopoietic and umbilical cord mesenchymal stem cells for severe aplastic anemia: Successful engraftment and mild GVHD
per: Wu Yamei, et al.
Publicat: (2014-01-01)

Extending duration of letermovir prophylaxis in haploidentical stem cell transplantation
per: Pongthep Vittayawacharin, et al.
Publicat: (2024-07-01)

GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT
per: Frédéric Baron, et al.
Publicat: (2023-02-01)

Impaired thymic iNKT cell differentiation at early precursor stage in murine haploidentical bone marrow transplantation with GvHD
per: Weijia Zhao, et al.
Publicat: (2023-08-01)

PB2439: EARLIER ENGRAFTMENT WITHOUT INCREASE OF GVHD IN HIGHER DOSE OF CD34+ CELLS IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION
per: Tran-Der Tan, et al.
Publicat: (2023-08-01)

Low-dose ATG combined with low-dose PTCY in preventing GVHD after haploidentical transplantation: a retrospective analysis of 90 cases
per: LEI Jinmei, et al.
Publicat: (2024-02-01)

Lower dose of ATG combined with basiliximab for haploidentical hematopoietic stem cell transplantation is associated with effective control of GVHD and less CMV viremia
per: Zhenli Huang, et al.
Publicat: (2022-11-01)

Melatonin inhibits Japanese encephalitis virus replication and neurotoxicity via calcineurin-autophagy pathways
per: Ji-Hong Moon, et al.
Publicat: (2023-11-01)

Low dose ATG-Fresenius for GVHD prophylaxis: a comparative study with ATG-Thymoglobulin
per: Itai Falicovich, et al.
Publicat: (2025-01-01)

Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation
per: Mi Kwon, et al.
Publicat: (2019-11-01)

Antigen-specific priming is dispensable in depletion of apoptosis-sensitive T cells for GvHD prophylaxis
per: Shai eYarkoni, et al.
Publicat: (2014-05-01)

Cyclosporine A-related neurotoxicity after haploidentical hematopoietic stem cell transplantation in children with hematopathy
per: Yong Wang, et al.
Publicat: (2021-04-01)

Post-transplantation cyclophosphamide combined with tacrolimus and low-dose post-engraftment anti-thymoglobulin as GVHD prophylaxis for patients undergoing peripheral blood stem cell transplantation from haploidentical family donor: A single center analysis
per: Wen-hui Gao, et al.
Publicat: (2023-03-01)

PTCy ameliorates GVHD by restoring regulatory and effector T-cell homeostasis in recipients with PD-1 blockade
per: Shuntaro Ikegawa, et al.
Publicat: (2019-12-01)

Nephro and neurotoxicity of calcineurin inhibitors and mechanisms of rejections: A review on tacrolimus and cyclosporin in organ transplantation
per: Zahra Tolou-Ghamari
Publicat: (2012-04-01)

Factors associated with difficult neuraxial blockade
per: Ružman T, et al.
Publicat: (2014-10-01)

INVITRO TREATMENT OF MARROW WITH ATCG OR CAMPATH-1 FOR PROPHYLAXIS OF GVHD - RESULTS OF THE AG-KMT MUNCHEN
per: Kolb, H, et al.
Publicat: (1985)

Towards a rational graft-versus-host disease (GVHD) prophylaxis: rituximab should not be forgotten
per: Marlies EHM Van Hoef
Publicat: (2013-04-01)

S242: EARLY INFUSION OF MSCS IN THE PROPHYLAXIS OF GVHD AFTER HAPLO-HEMATOPOIETIC STEM-CELL TRANSPLANTATION
per: R. Huang, et al.
Publicat: (2022-06-01)

HSCT with Mismatched Unrelated Donors (MMUD): A Comparison of Different Platforms for GvHD Prophylaxis
per: Massimo Berger, et al.
Publicat: (2022-02-01)

Lower Absolute Lymphocyte Count Before Conditioning Predicts High Relapse Risk in Patients After Haploidentical Peripheral Blood Stem Cell Transplantation With Low Dose Anti-Thymocyte Globulin/Post-Transplant Cyclophosphamide for GvHD Prophylaxis
per: Xiao Zhou, et al.
Publicat: (2022-02-01)

GVHD TREATMENT
per: Elif BirtaşAteşoğlu
Publicat: (2021-11-01)

Mehta RS, Ramdial J, Kebriaei P, et al. Haploidentical vs HLA-matched sibling donor HCT with PTCy prophylaxis: HLA factors and donor age considerations. Blood Adv. 2024;8(20):5306-5314.
Publicat: (2025-01-01)

Multicentre adaptive randomised trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin versus calcineurin inhibitor-based or sirolimus-based post-transplant cyclophosphamide (Methods of T cell Depletion, MoTD trial)
per: Simon Gates, et al.
Publicat: (2025-01-01)

Comparative retrospective analysis of cord blood transplantation with ATG-containing conditioning regimens and haploidentical stem cell transplantation: similar survival outcomes with reduced incidence of GVHD
per: Yongjia Liu, et al.
Publicat: (2025-12-01)

The immunopathology of thymic GVHD.
per: Krenger, W, et al.
Publicat: (2008)

The thymus in GVHD pathophysiology.
per: Krenger, W, et al.
Publicat: (2008)

Calcineurin
per: Trevor P. Creamer
Publicat: (2020-08-01)

Similar Survival But Less Chronic GVHD in Antithymocyte Globulin–Based Myeloablative Haploidentical Transplant Compared With Matched Sibling Transplant for Adult T-cell Acute Lymphoblastic Leukemia/Lymphoma
per: Zhenyang Gu, et al.
Publicat: (2024-08-01)

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT) IN CHILDREN AND ADOLESCENTS WITH SICKLE CELL DISEASE (SCD): A FEASIBLE CURATIVE OPTION WITH HLA-IDENTICAL OR HAPLOIDENTICAL DONORS
per: RV Gouveia, et al.
Publicat: (2024-10-01)

Longitudinal relationship between the gut microbiota variation and diversity and gut graft-versus-host disease (GVHD) following pediatric allogeneic hematopoietic cell transplantation (HCT) – Case series
per: Ashley N. Gray, et al.
Publicat: (2023-05-01)